Neothetics (NEOT) Getting Favorable News Coverage, Report Shows
News stories about Neothetics (NASDAQ:NEOT) have been trending positive on Monday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neothetics earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.0744317221226 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, ValuEngine downgraded Neothetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 27th.
Shares of Neothetics (NASDAQ:NEOT) traded down 6.809% during mid-day trading on Monday, hitting $0.438. The company had a trading volume of 467,006 shares. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $1.28. Neothetics has a 12 month low of $0.30 and a 12 month high of $2.63. The company’s market cap is $6.06 million.
Neothetics (NASDAQ:NEOT) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20). On average, analysts expect that Neothetics will post ($0.61) EPS for the current year.
Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
Receive News & Stock Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related stocks with our FREE daily email newsletter.